Mesothelin and immunotherapy for pancreatic cancer / 中华内分泌外科杂志
Chinese Journal of Endocrine Surgery
; (6): 510-513, 2019.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-823650
Biblioteca responsável:
WPRO
ABSTRACT
As one of the most lethal malignancies, pancreatic cancer and its therapy remains a big prob-lem all around the world. With the few candidates for surgery and the poor outcome for chemotherapy, the im-munotherapy becomes one important direction. Mesothelin, a membrane protein, expresses at low levels in normal tissues, but is re-expressed at a high frequency in pancreatic cancer, which makes mesothelin an ideal target for im-munotherapy.This review summarizes the progression of mesothein-targeted immunotherapy for pancreatic cancer.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Journal of Endocrine Surgery
Ano de publicação:
2019
Tipo de documento:
Artigo